We are witnessing an explosion of new information related to the intersecting health problems of obesity and cardiovascular disease. A flurry of cardiovascular outcomes trials have demonstrated a remarkable, yet poorly understood, cardioprotective benefit of diabetes and obesity drugs. In parallel, recent breakthrough technologies and experimental approaches allow deep real-time interrogation of systemic, organ, and cellular metabolism. We propose a symposium designed to address a series of topics relevant to cardiometabolism in health and disease including: 1) the metabolic bases for heart and vascular health/disease; 2) organ-organ crosstalk relevant to the synergism between obesity, insulin resistance, and cardiovascular disease; 3) the mechanisms whereby new drugs such as SGLT2 inhibitors and GLP-1r agonists reduce cardiovascular events; and 4) the impact of environmental factors such as feeding and diurnal behavior on cardiovascular health and disease. A successful Symposium focused on these topics requires participants with expertise across an array of disciplines and themes including cellular and organismal metabolism, heart and vascular biology/physiology/disease, clinical and data science, clinical trial design, and new drug seekers. The proposed 'Cardiometabolism in Health and Disease' symposium will be most appealing if partnered with a symposium centered around obesity and its complications. It is envisioned that this conference will bring together basic and translational scientists in academia with industry partners engaged in the development and assessment of new treatments for the worldwide health problem of cardiometabolic diseases. Such a meeting will be timely and of significant interest to a wide range of participants.